WASHINGTON (dpa-AFX) - St. Jude Medical Inc. (STJ) announced Monday that it has received approval from the U.S. Food and Drug Administration or FDA for the Allure Quadra Cardiac Resynchronization Therapy Pacemaker or CRT-P, which provides additional pacing innovations for physicians to treat patients with heart failure.
The company also announced FDA approvals for the Assurity pacemaker and Endurity pacemaker families of devices.
The Allure Quadra CRT-P and the Assurity and Endurity pacemakers received CE Mark in March 2013. The company plans to launch these products in the U.S. by the end of the first quarter in 2014.
Copyright RTT News/dpa-AFX